- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02523638
Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (PEN-PV)
An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients
Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and frequently also of white blood cells. The "thickening" of the blood in relation with a modified function of the cells has several consequences like increased blood pressure, pruritus of the skin, fatigue, disturbed blood circulation in the brain as well as fingers and toes and an increased risk of arterial and venous thrombosis (thrombosis is the formation of a blood clot in a vessel); like stroke, cardiac infarction, deep vein thrombosis in the legs. In case of a strong increase of platelets there is an additional risk of bleedings. As the disease progresses the size of spleen and liver increased in most cases and the bone marrow shows signs of fibrosis. In some cases of PV a progression at a later time point to a leukemia (increased formation of white blood cells) can occur.
The aim of this study is to assess the ease of AOP2014 self-administration using dedicated questionnaires.
- To assess safety and tolerability: adverse events (AEs), laboratory parameters, electrocardiogram (ECG) throughout study.
- To assess maintenance of the blood efficacy parameters Hct (Hematocrit), WBC (white blood cells) and PLTs (platelets) and spleen size (comparing values at Visit P7 vs. values at Visit P1).
- To assess the feasibility of AOP2014 self-administration: defined as the ability of the patients to use the pen as a self-administration tool (ease of handling, safety, tolerability and efficacy).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Graz, Austria
- LKH Graz
-
Innsbruck, Austria
- University Hospital Innsbruck
-
Linz, Austria
- Elisabethinen Hospital Linz
-
Salzburg, Austria
- Salzburg Regional Hospital
-
Vienna, Austria
- Medical University Vienna
-
Vienna, Austria
- Hanusch Hospital
-
Wels, Austria
- Hospital Wels-Grieskirchen
-
-
-
-
-
Sofia, Bulgaria
- Specialized Hospital for Active Treatment of Hematological Diseases
-
Vratsa, Bulgaria
- Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine
-
-
-
-
-
Brno, Czech Republic
- University Hospital Brno
-
Hradec Kralove, Czech Republic
- University Hospital Hradec Kralove
-
Prague, Czech Republic
- Institute of Hematology and Blood Transfusion
-
Prague, Czech Republic
- University Hospital Kralovske Vinohrady
-
Prague, Czech Republic
- University Hospital Motol
-
-
-
-
-
Marseilles, France
- Institute Paoli-Calmettes
-
Paris, France
- Hôspital Saint-Louis
-
Poitiers, France
- Clinical Research Center CIC
-
-
-
-
-
Budapest, Hungary
- St Istvan and St Laszlo Hospital of Budapest
-
Debrecen, Hungary
- University of Debrecen
-
Gyula, Hungary
- Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology
-
Kaposvar, Hungary
- Kaposi Mór County Teaching Hospital
-
Szeged, Hungary
- University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6
-
-
-
-
-
Katowice, Poland
- Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice
-
Krakow, Poland
- University Hospital in Cracow
-
Lublin, Poland
- Independent Public Teaching Hospital No.1 in Lublin
-
Rzeszow, Poland
- Fryderyk Chopin Provincial Specialized Hospital
-
Torun, Poland
- Nicolaus Copernicus Municipal Specialist Hospital
-
Warsaw, Poland
- Institute of Hematology and Transfusion Medicine
-
-
-
-
-
Banska Bystrica, Slovakia
- University Hospital with Outpatient Clinic F.D. Roosevelt
-
Bratislava, Slovakia
- Saint Cyril and Metod University Hospital Bratislava
-
-
-
-
-
Cherkasy, Ukraine
- Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center
-
Dnipropetrovsk, Ukraine
- Dnipropetrovsk City Multispecialty Clinical Hospital #4
-
Kiev, Ukraine
- National Research Center for Radiation Medicine, Institute of Clinical Radiology
-
Lviv, Ukraine
- Institute of blood pathology and transfusion medicine
-
Zhytomyr, Ukraine
- O.F. Herbachevskyi Regional Clinical Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients who either completed the 12 months AOP2014 treatment arm of the PROUD-PV study, or are currently participating in the CONTINUATION-PV, and at the "EoT visit" (End of treatment visit) of the PROUD-PV study or two weeks after the last assessment visit of the CONTINUATION-PV study, fulfill at least one of the following criteria:
- Normalization of at least two out of three main blood parameters (Hct (Hematocrit), PLTs (Platelets) and WBCs (white blood cells) if these parameters were moderately increased (Hct<50%, WBCs<20 x 109/L, PLTs<600 x 109/L) at baseline visit of the PROUD-PV study, OR
- >35% decrease of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were massively increased (Hct>50%, WBCs>20 x 109/L, PLTs >600 x 109/L), at baseline visit of the PROUD-PV study, OR
- Normalization of spleen size, if spleen was enlarged at baseline visit of the PROUD-PV study, OR
- Otherwise a clear, medically verified benefit from treatment with AOP2014 (e.g. normalization of disease-related micro-vasculatory symptoms, substantial decrease of JAK2 (Januskinase 2) allelic burden).
- Signed written ICF.
Exclusion Criteria:
Withdrawal criteria, as specified in the PROUD-PV and CONTINUATION-PV studies, which mandate treatment discontinuation.
- Non-recovery from the AOP2014 related toxicities to the grade (usually, Grade I) which allows continuation of the treatment.
- HADS (Hospital Anxiety and Depression Scale) score of 11 or higher on either or both of the subscales, and /or development or worsening of clinically significant depression or suicidal thoughts.
- Progressive and clinically significant increase of liver enzyme levels despite dose reduction, or if such increase is accompanied by increased bilirubin level, any signs or symptoms of a clinically significant autoimmune disease.
- Clinically significant development of a new ophthalmologic disorder, or worsening of a pre-existing one, during the study.
- Loss of efficacy of AOP2014 or any comparable situation where no further benefits of treatment continuation are expected by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Pegylated- Proline-Interferon alpha-2b
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen single arm
|
Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate ease of self-administration of AOP2014
Time Frame: 3 months
|
To evaluate ease of self-administration of AOP2014 as assessed by staff and patients using dedicated questionnaires, using rates of full success and failure rates (defined in the statistics section of the synopsis).
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event
Time Frame: 3 month
|
biweekly, using dedicated questionnaires
|
3 month
|
number of phlebotomies
Time Frame: 3 months
|
biweekly
|
3 months
|
Disease response
Time Frame: 3 months
|
The main efficacy evaluation criterion will be disease response defined as: • Hct (Hematocrit)< 45% without phlebotomy (at least 3 months since the last phlebotomy). The hematological parameters will be measured by the local laboratories at clinical sites. |
3 months
|
Disease response
Time Frame: 3 months
|
The main efficacy evaluation criterion will be disease response defined as: • PLTs (Platelets)< 400 x 109/L. The hematological parameters will be measured by the local laboratories at clinical sites. |
3 months
|
Disease response
Time Frame: 3 months
|
The main efficacy evaluation criterion will be disease response defined as: • WBCs (White blood cells)< 10 x 109/L. The hematological parameters will be measured by the local laboratories at clinical sites. |
3 months
|
blood parameters
Time Frame: 3 months
|
first biweekly than monthly The main efficacy evaluation criterion will be disease response defined as: • Hct< 45% without phlebotomy (at least 3 months since the last phlebotomy). The hematological parameters will be measured by the local laboratories at clinical sites. |
3 months
|
blood parameters
Time Frame: 3 months
|
first biweekly than monthly The main efficacy evaluation criterion will be disease response defined as: • WBCs< 10 x 109/L. The hematological parameters will be measured by the local laboratories at clinical sites. |
3 months
|
blood parameters
Time Frame: 3 months
|
first biweekly than monthly The main efficacy evaluation criterion will be disease response defined as: • PLTs< 400 x 109/L. The hematological parameters will be measured by the local laboratories at clinical sites. |
3 months
|
spleen size
Time Frame: 3 months
|
locally, Sonography will be used for measuring the spleen size (length).
at Visit 1 and at the End of the study (week 12)
|
3 months
|
disease related symptoms
Time Frame: 3 months
|
biweekly, using dedicated questionnaires
|
3 months
|
protocol-specific adverse events of special interest
Time Frame: 3 months
|
biweekly, using dedicated questionnaires
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Heinz Gisslinger, MD, Med Uni Wien
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Polycythemia Vera
- Polycythemia
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Interferon alpha-2
Other Study ID Numbers
- PEN-PV
- 2014-001356-31 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycythemia Vera
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan
-
Novartis PharmaceuticalsCompletedPolycythemia Vera (PV)United States
-
PharmaEssentia Japan K.K.Recruiting
-
PharmaEssentia Japan K.K.CompletedPolycythemia Vera (PV)Japan
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
Ionis Pharmaceuticals, Inc.RecruitingPhlebotomy Dependent Polycythemia VeraUnited States, Canada, Hungary, United Kingdom, Australia, Poland
-
Northwestern UniversityNational Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma SocietyWithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis PhaseUnited States
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Clinical Trials on Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
-
Institute of Hematology & Blood Diseases Hospital...RecruitingEssential ThrombocytopeniaChina
-
Philipps University Marburg Medical CenterDeutsche Krebshilfe e.V., Bonn (Germany); AOP Orphan Pharmaceuticals AGCompletedChronic Myeloid Leukemia in RemissionFrance, Germany
-
AOP Orphan Pharmaceuticals AGPharmaEssentia Corporation (for the U.S.)CompletedPolycythemia VeraSpain, Austria, Bulgaria, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine, Czechia
-
Merck Sharp & Dohme LLCTerminated
-
Emory UniversityBayerCompleted
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedLymphomaUnited States
-
Merck Sharp & Dohme LLCCompleted
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedLiver Transplantation | Liver Cirrhosis | Hepatitis C, Chronic